Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z A Massy

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
Kidney International. Supplement|December 1, 1995
Clinical predictors of chronic renal allograft rejectionZ A Massy, C Guijarro, B L Kasiske
Lancet (London, England)|January 13, 1996
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?Z A Massy, W F Keane, B L Kasiske
Nephron|January 1, 1996
Serum lipoprotein (a) levels in renal transplantation: role of renal functionZ A Massy, T Drüeke, H Kreis, et al.
Seminars in Nephrology|December 16, 2014
The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)D J A Goldsmith, Z A Massy, V Brandenburg
Nephrologie|January 1, 1993
[Anomalies of lipoprotein metabolism in chronic renal insufficiency]B Lacour, Z A Massy, P Jungers, et al.
Diabetes & Metabolism|April 12, 2008
The pathophysiology of vascular calcification: are osteoclast-like cells the missing link?Z A Massy, R Mentaverri, A Mozar, et al.
Nephrologie|January 23, 1999
[Incidence of atherosclerotic cardiovascular events in patients with chronic uremia: epidemiologic studies in Ile-de-France]P Jungers, T Nguyen Khoa, Z A Massy, et al.
Kidney International. Supplement|December 1, 1995
Chronic renal allograft rejection and clinical trial designB L Kasiske, Z A Massy, C Guijarro, et al.
Kidney International Reports|August 15, 2025
Response to the Letter to the Editor Entitled "Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits"M Costes-Albrespic, N Alencar de Pinho, Z A Massy, et al.
Kidney International|July 1, 1995
Lipid-lowering therapy in patients with renal diseaseZ A Massy, J Z Ma, T A Louis, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Kidney International. Supplement|December 1, 1995
Clinical predictors of chronic renal allograft rejectionZ A Massy, C Guijarro, B L Kasiske
Lancet (London, England)|January 13, 1996
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?Z A Massy, W F Keane, B L Kasiske
Nephron|January 1, 1996
Serum lipoprotein (a) levels in renal transplantation: role of renal functionZ A Massy, T Drüeke, H Kreis, et al.
Seminars in Nephrology|December 16, 2014
The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)D J A Goldsmith, Z A Massy, V Brandenburg
Nephrologie|January 1, 1993
[Anomalies of lipoprotein metabolism in chronic renal insufficiency]B Lacour, Z A Massy, P Jungers, et al.
Diabetes & Metabolism|April 12, 2008
The pathophysiology of vascular calcification: are osteoclast-like cells the missing link?Z A Massy, R Mentaverri, A Mozar, et al.
Nephrologie|January 23, 1999
[Incidence of atherosclerotic cardiovascular events in patients with chronic uremia: epidemiologic studies in Ile-de-France]P Jungers, T Nguyen Khoa, Z A Massy, et al.
Kidney International. Supplement|December 1, 1995
Chronic renal allograft rejection and clinical trial designB L Kasiske, Z A Massy, C Guijarro, et al.
Kidney International Reports|August 15, 2025
Response to the Letter to the Editor Entitled "Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits"M Costes-Albrespic, N Alencar de Pinho, Z A Massy, et al.
Kidney International|July 1, 1995
Lipid-lowering therapy in patients with renal diseaseZ A Massy, J Z Ma, T A Louis, et al.
Pageof 9